Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Dec;30(6):874–876. doi: 10.1128/aac.30.6.874

Pharmacokinetics of cefoperazone in the parturient.

B Gonik, S Feldman, L K Pickering, C G Doughtie
PMCID: PMC180610  PMID: 3813513

Abstract

Limited pharmacokinetic data for cefoperazone are available from the parturient. Because cefoperazone has a dual excretory pattern, primarily via the biliary system and secondarily via the kidney, pregnancy-induced physiologic alterations can influence its deposition and clearance. Twelve term parturients receiving cefoperazone prophylaxis after cesarean section were selected for study. After 2 g of cefoperazone was administered for 1 h intravenously, serial blood samples were assayed by high-pressure liquid chromatography. Plasma protein binding of cefoperazone was studied in vitro. The mean peak cefoperazone concentration +/- standard deviation was 169.9 +/- 60.4 micrograms/ml. The mean half-life was 152 min. Total serum clearance was 80.8 +/- 30.8 ml/min. The steady-state volume of distribution was 14.2 +/- 6.0 liters. All subjects had detectable trough levels at the end of the dosage interval, with a mean value of 6.5 +/- 5.2 micrograms/ml. Protein binding of cefoperazone for parturients was 74.3 +/- 10.9%, compared with 87.7 +/- 3.2% in nonpregnant controls (P less than 0.05). These data suggest that cefoperazone deposition can be greatly influenced by pregnancy. However, unlike several other new antimicrobial agents whose excretions are mainly renal, the cefoperazone half-life and thus trough concentration for the parturient more closely resemble that for the nonpregnant subject.

Full text

PDF
874

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Gonik B., Cotton D. B., Feldman S., Cleary T. G., Pickering L. K. Pharmacokinetics of cefotaxime in the postpartum patient. Am J Perinatol. 1985 Apr;2(2):114–117. doi: 10.1055/s-2007-999926. [DOI] [PubMed] [Google Scholar]
  2. Gonik B., Cotton D., Feldman S., Cleary T. G., Pickering L. K. Comparative pharmacokinetics of cefoxitin in postpartum normotensive and pregnancy-induced hypertensive patients. Am J Obstet Gynecol. 1984 Apr 15;148(8):1088–1091. doi: 10.1016/0002-9378(84)90633-1. [DOI] [PubMed] [Google Scholar]
  3. Greenfield R. A., Gerber A. U., Craig W. A. Pharmacokinetics of cefoperazone in patients with normal and impaired hepatic and renal function. Rev Infect Dis. 1983 Mar-Apr;5 (Suppl 1):S127–S136. doi: 10.1093/clinids/5-supplement_1.s127. [DOI] [PubMed] [Google Scholar]
  4. Hemsell D. L., Cunningham F. G. Combination antimicrobial therapy for serious gynecological and obstetrical infections--obsolete? Clin Ther. 1981;4 (Suppl A):81–88. [PubMed] [Google Scholar]
  5. Kemmerich B., Lode H., Belmega G., Jendroschek T., Borner K., Koeppe P. Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam. Antimicrob Agents Chemother. 1983 Mar;23(3):429–434. doi: 10.1128/aac.23.3.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kemmerich B., Lode H., Borner K., Belmega D., Jendroschek T., Koeppe P., Goertz G. Biliary excretion and pharmacokinetics of cefoperazone in humans. J Antimicrob Chemother. 1983 Jul;12(1):27–37. doi: 10.1093/jac/12.1.27. [DOI] [PubMed] [Google Scholar]
  7. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  8. Neu H. C., Fu K. P., Aswapokee N., Aswapokee P., Kung K. Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin. Antimicrob Agents Chemother. 1979 Aug;16(2):150–157. doi: 10.1128/aac.16.2.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Nöschel H., Peiker G., Müller B., Schröder S., Bonow A., Meinhold P., Voigt R., Tittel R. Pharmacokinetics during pregnancy and delivery. Int J Biol Res Pregnancy. 1982;3(2):66–68. [PubMed] [Google Scholar]
  10. Standiford H. C., Drusano G. L., McNamee W. B., Tatem B., Ryan P. A., Schimpff S. C. Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers. Rev Infect Dis. 1982 Nov-Dec;4 (Suppl):S585–S594. doi: 10.1093/clinids/4.supplement_3.s585. [DOI] [PubMed] [Google Scholar]
  11. Strausbaugh L. J., Llorens A. S. Cefoperazone therapy for obstetric and gynecologic infections. Rev Infect Dis. 1983 Mar-Apr;5 (Suppl 1):S154–S160. doi: 10.1093/clinids/5.supplement_1.s154. [DOI] [PubMed] [Google Scholar]
  12. Yoshikawa T., Sugiyama Y., Sawada Y., Iga T., Hanano M., Kawasaki S., Yanagida M. Effect of late pregnancy on salicylate, diazepam, warfarin, and propranolol binding: use of fluorescent probes. Clin Pharmacol Ther. 1984 Aug;36(2):201–208. doi: 10.1038/clpt.1984.163. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES